Biotech Startups

Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.

1 investor

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing retinal disease treatments, specifically engineered biologics for wet AMD, diabetic eye disease, and retinal vein occlusion. The company focuses on reducing patient treatment burden through extended-duration therapies that require fewer clinic visits.

1 investor

ALLOX develops an AI-enabled platform that uses high-throughput genomics and machine learning to discover biophysical parameters governing protein function for drug discovery. The company focuses on identifying allosteric drug targets to enable development of therapies for previously undruggable proteins.

1 investor

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions. Its lead program is an orally administered pan-ROCK inhibitor being investigated in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.

1 investor

Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.

1 investor

Allumbra combines quantum sensing technology with AI to analyze blood samples for early cancer detection. The company develops liquid biopsy tests that identify molecular signals of cancer before tumors become visible.

1 investor

Allumin8 develops 3D-printed porous titanium pedicle screws and bone marrow delivery systems designed to improve spinal fusion outcomes and reduce screw loosening and revision rates. The company serves the orthopedic and spine surgery market with therapeutic hardware intended to promote bone ingrowth and osseointegration.

1 investor

Ally Bridge Group is a healthcare investment management firm investing across the global life sciences industry through complementary private equity and public equity strategies. It operates across the capital structure with offices in New York and Hong Kong, serving investors seeking exposure to healthcare innovation.

1 investor

Biotech addressing immune response issues that limit the safety and efficacy of in vivo gene therapies.

1 investor

Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at a tumor site during biopsy or resection surgery to activate the immune system and make patients more responsive to checkpoint immunotherapy. It targets advanced solid tumors across multiple tumor types and disease stages.

1 investor

Alp Bio operates a platform that combines human tonsil organoid technology with protein AI models to assess and reduce immunogenicity (anti-drug antibody) risk in therapeutic antibodies before clinical development. It serves biologics developers with in-silico ADA screening, ex vivo tonsil organoid assays, and generative redesign of antibody sequences.

1 investor

Alpenglow Biosciences develops AI-enabled 3D tissue imaging and spatial profiling platforms for researchers and clinical teams in pathology and diagnostics. The company's patented light-sheet microscopy technology provides volumetric tissue data for analysis and clinical discovery applications.

1 investor

Alpha Cancer Technologies (ACT) is a biopharmaceutical company developing and commercializing targeted immuno-oncology and immunomodulation therapies. It operates in the cancer therapeutics space.

1 investor

Alpha Cognition develops ZUNVEYL (benzgalantamine), a cholinesterase inhibitor approved for treating mild to moderate dementia of the Alzheimer's type in adults. The company operates in the pharmaceutical sector focused on central nervous system and neurodegenerative disease therapeutics.

1 investor

A biopharmaceutical company developing oncology treatments including EGFR-targeting small molecule drugs for lung cancer with CNS penetration, and expanding into cell immunotherapy through licensed partnerships for NK cell and CAR-T therapies targeting solid tumors and hematologic malignancies.

1 investor

EMBL's European Bioinformatics Institute (EMBL-EBI) manages open biological data resources and provides tools for browsing data, performing analyses, and sharing research results. It also offers bioinformatics training, research programmes, and industry partnerships, serving scientists across Europe as part of the intergovernmental EMBL organisation.

1 investor

Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.

1 investor

Alsteni Medical develops an intraoral gastrointestinal access device designed to deliver nutrient therapy for metabolic management. The company is advancing the device through FDA 510(k) clearance with clinical evidence and manufacturing partnerships in place.

1 investor

Alta Partners is a venture capital firm focused on life sciences and healthcare investments, with a portfolio that has generated over 90 FDA-approved products and includes both therapeutic companies and tech-enabled patient care services.

1 investor

Altach Biomedical develops cartilage repair solutions for the orthopedic medical device industry. The company showcases its innovative technologies at major MedTech conferences to engage with investors and strategic partners.

1 investor

ALTDATA builds physics-anchored digital twins and privacy-safe synthetic data to address data scarcity for research-intensive teams in biotech, healthcare, and space. The Adelaide-based company serves biomedical researchers and space agencies who face barriers to accessing or generating experimental data.

1 investor

AlterDiag is a diagnostics company founded by executives with backgrounds in immunology R&D and business strategy. The page focuses on the founding team and does not detail the specific product beyond its work in the diagnostics market.

1 investor

Alter Echo develops technology that keeps personnel outside cleanrooms while reducing disposable gown waste in pharmaceutical manufacturing. The company targets pharmaceutical facilities seeking to improve workplace safety, environmental sustainability, and operational efficiency.

1 investor

Alternative Plants uses plant stem cell technology and cellular farming to produce active cosmetic ingredients derived from rare, endangered, or hard-to-access plants. It supplies these in vitro and dermatologically tested botanical extracts to the cosmetics and skincare industry.

1 investor